Triple Negative Breast Cancer
Triple negative breast cancers, up to 15%-20% of all breast cancers, are those that do not express estrogen, progesterone, or her2. Therefore, the targeted therapies of hormonal treatments (tamoxifen and the AIs) and herceptin are not relevant. This is a review article, a clinical update, about treatment of triple negative breast from Community Oncology. Here is a paragraph and then a link if you want to read the whole article:
Triple-negative breast cancer:
a clinical update
Darrel W. Cleere, RN, CCRP | Department of Surgery, The Methodist Hospital, Houston, Texas
Accounting for approximately 15%-20% of breast cancers, triple-negative breast cancers (TNBCs) are tumors that do not express estrogen receptor, progesterone receptor, or human epidermal growth factor 2. Most tumors in this breast cancer subtype share a similar molecular profile and exhibit aggressive behavior, distinct metastatic pattern, and poor prognosis. In general, patients with early-stage TNBC have better chemotherapy response rates than patients with non-TNBC; however, patients with TNBC not achieving a pathologic complete response (pCR) with adjuvant chemotherapy are more likely to face early relapse, visceral metastasis, and shorter survival.
Chemotherapy-based regimens that maximize the rate of pCR offer the best treatment approach for TNBC at this time, but several novel strategies are undergoing clinical evaluation in TNBC: the cytotoxic agent ixabepilone and targeted inhibitors of angiogenesis, growth factor receptors, poly (ADP-ribose) polymerase 1 (PARP 1), and others. Future insights into TNBC biology will improve therapeutic strategies for patients with this disease.